The article is devoted to the risk of cardiovascular disease in coronavirus infection. In March 2020, the World Health Organization announced the COVID-19 pandemic. The virus set many tasks for practicing doctors, including the study of its pathogenesis and the creation of a therapy suitable for all patient groups. This paper presents information about cellular entry of the coronavirus, the development of cardiovascular diseases, in particular, the heart, and the latest data on experimental therapy with hydroxychloroquine. Coronavirus has been shown to affect the synthesis of angiotensin 2, which increase the QT interval. At the same time, the combination therapy using chloroquine and azithromycin caused a critical prolongation of the QT interval in some cases. On 4 July 2020, WHO accepted the Solidarity Trial’s International Steering Committee recommendation has stop the trial of these drugs. Cardiologists should review the latest information on the effects of coronavirus on the cardiovascular system and based on this, make recommendations the management and treatment of severe patients.